▶ 調査レポート

網膜障害治療の世界市場:疾患適応症(黄斑変性症、糖尿病性網膜症、糖尿病性黄斑浮腫、その他)、治療クラス別(抗VEGF剤、その他(抗炎症薬、その他))、剤形別(ジェル、目薬、カプセル&タブレット、点眼薬、軟膏)、流通経路別(病院薬局、小売薬局、オンライン販売)

• 英文タイトル:Retinal Disorder Treatment Market (Disease Indication: Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, and Others; Therapeutic Class: Anti-VEGF Agents and Others (Anti-inflammatory Drugs, etc.); Dosage Form: Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。網膜障害治療の世界市場:疾患適応症(黄斑変性症、糖尿病性網膜症、糖尿病性黄斑浮腫、その他)、治療クラス別(抗VEGF剤、その他(抗炎症薬、その他))、剤形別(ジェル、目薬、カプセル&タブレット、点眼薬、軟膏)、流通経路別(病院薬局、小売薬局、オンライン販売) / Retinal Disorder Treatment Market (Disease Indication: Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, and Others; Therapeutic Class: Anti-VEGF Agents and Others (Anti-inflammatory Drugs, etc.); Dosage Form: Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / D0JU09126資料のイメージです。• レポートコード:D0JU09126
• 出版社/出版日:Transparency Market Research / 2020年1月22日
• レポート形態:英文、PDF、225ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥637,450 (USD5,795)▷ お問い合わせ
  Multi User¥967,450 (USD8,795)▷ お問い合わせ
  Corporate License¥1,297,450 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、網膜障害治療の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場概要、疾患適応症(黄斑変性症、糖尿病性網膜症、糖尿病性黄斑浮腫、その他)分析、治療クラス別(抗VEGF剤、その他(抗炎症薬、その他))分析、剤形別(ジェル、目薬、カプセル&タブレット、点眼薬、軟膏)分析、流通経路別(病院薬局、小売薬局、オンライン販売)分析、地域別分析、競争分析などの構成でお届けいたします。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場動向
・市場概要
・網膜障害治療の世界市場:疾患適応症(黄斑変性症、糖尿病性網膜症、糖尿病性黄斑浮腫、その他)
・網膜障害治療の世界市場:治療クラス別(抗VEGF剤、その他(抗炎症薬、その他))
・網膜障害治療の世界市場:剤形別(ジェル、目薬、カプセル&タブレット、点眼薬、軟膏)
・網膜障害治療の世界市場:流通経路別(病院薬局、小売薬局、オンライン販売)
・網膜障害治療の世界市場:地域別
・競争分析

Retinal Disorder Treatment Market – Scope of the Report

TMR’s report on the global retinal disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2019 to 2027. The report provides revenue of the retinal disorder treatment market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the retinal disorder treatment market from 2019 to 2027.

The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involved reaching out to key players’ product literature, annual reports, press releases, and relevant documents to understand the retinal disorder treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the retinal disorder treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the retinal disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the retinal disorder treatment market.

The report delves into the competitive landscape of the retinal disorder treatment market. Key players operating in the retinal disorder treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the retinal disorder treatment market that are profiled in this report.

Key Questions Answered in TMR’s Report on Retinal Disorder Treatment Market

What is the sales/revenue generated by retinal disorder treatment products across all regions during the forecast period?
What are the opportunities in the retinal disorder treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
In which region is the retinal disorder treatment market set to expand at the fastest CAGR during the forecast period?
Which product segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Retinal Disorder Treatment Market – Research Objectives and Research Approach

The comprehensive report on the retinal disorder treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the retinal disorder treatment market, in terms of disease indication, therapeutic class, dosage form, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the retinal disorder treatment market.

レポート目次

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights

2. Assumptions and Research Methodology

2.1. Assumptions

2.2. Research Methodology

3. Executive Summary

3.1. Global Retinal Disorder Treatment Market Snapshot

4. Market Overview

4.1. Product Overview

4.2. Key Industry Events

4.3. Market Dynamics

4.3.1. Drivers and Restraints Snapshot Analysis

4.3.2. Drivers

4.3.3. Restraints

4.3.4. Opportunities

4.4. Global Retinal Disorder Treatment Market Revenue Projection

4.5. Global Retinal Disorder Treatment Market Outlook

5. Market Outlook

5.1. Clinical Trial Analysis

5.2. Regulatory Scenario

5.3. Pipeline Analysis

5.4. Key Mergers & Acquisitions

5.5. Reimbursement Scenario

6. Global Retinal Disorder Treatment Market Analysis, by Disease Indication

6.1. Introduction

6.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

6.3. Global Retinal Disorder Treatment Market Forecast, by Disease Indication

6.3.1. Macular Degeneration

6.3.1.1. Dry Macular Degeneration

6.3.1.2. Wet Macular Degeneration

6.3.2. Diabetic Retinopathy

6.3.3. Diabetic Macular Edema

6.3.4. Others (Retinal Vein Occlusion, etc.)

7. Global Retinal Disorder Treatment Market Analysis, by Therapeutic Class

7.1. Introduction

7.2. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

7.3. North America Retinal Disorder Treatment Market Forecast, by Therapeutic Class

7.3.1. Anti-VEGF Agents

7.3.2. Others (Anti-inflammatory Drugs, etc.)

8. Global Retinal Disorder Treatment Market Analysis, by Dosage Form

8.1. Introduction

8.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

8.3. Global Retinal Disorder Treatment Market Forecast, by Dosage Form

8.3.1. Gels

8.3.2. Eye Solutions

8.3.3. Capsules & Tablets

8.3.4. Eye Drops

8.3.5. Ointments

8.4. Global Retinal Disorder Treatment Market Analysis, by Dosage Form

9. Global Retinal Disorder Treatment Market Analysis, by Distribution Channel

9.1. Introduction

9.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

9.3. Global Retinal Disorder Treatment Market Forecast, by Distribution Channel

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Sales

9.4. Global Retinal Disorder Treatment Market Analysis, by Distribution Channel

10. Global Retinal Disorder Treatment Market Analysis, by Region

10.1. Global Retinal Disorder Treatment Market Scenario, by Country

10.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Region

10.3. Global Retinal Disorder Treatment Market Forecast, by Region

10.3.1. North America

10.3.2. Europe

10.3.3. Asia Pacific

10.3.4. Latin America

10.3.5. Middle East & Africa

11. North America Retinal Disorder Treatment Market Analysis

11.1. Key Findings

11.2. North America Retinal Disorder Treatment Market Overview

11.3. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country

11.4. North America Retinal Disorder Treatment Market Forecast, by Country

11.4.1. U.S.

11.4.2. Canada

11.5. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

11.6. North America Retinal Disorder Treatment Market Forecast, by Disease Indication

11.6.1. Macular Degeneration

11.6.1.1. Dry Macular Degeneration

11.6.1.2. Wet Macular Degeneration

11.6.2. Diabetic Retinopathy

11.6.3. Diabetic Macular Edema

11.6.4. Others (Retinal Vein Occlusion, etc.)

11.7. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

11.8. North America Retinal Disorder Treatment Market Forecast, by Therapeutic Class

11.8.1. Anti-VEGF Agents

11.8.2. Others (Anti-inflammatory Drugs, etc.)

11.9. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

11.10. North America Retinal Disorder Treatment Market Forecast, by Dosage Form

11.10.1. Gels

11.10.2. Eye Solutions

11.10.3. Capsules & Tablets

11.10.4. Eye Drops

11.10.5. Ointments

11.11. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

11.12. North America Retinal Disorder Treatment Market Forecast, by Distribution Channel

11.12.1. Hospital Pharmacies

11.12.2. Retail Pharmacies

11.12.3. Online Sales

12. Europe Retinal Disorder Treatment Market Analysis

12.1. Key Findings

12.2. Europe Retinal Disorder Treatment Market Overview

12.3. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

12.4. Europe Retinal Disorder Treatment Market Forecast, by Country/Sub-region

12.4.1. Germany

12.4.2. France

12.4.3. U.K.

12.4.4. Italy

12.4.5. Spain

12.4.6. Rest of Europe

12.5. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

12.6. Europe Retinal Disorder Treatment Market Forecast, by Disease Indication

12.6.1. Macular Degeneration

12.6.1.1. Dry Macular Degeneration

12.6.1.2. Wet Macular Degeneration

12.6.2. Diabetic Retinopathy

12.6.3. Diabetic Macular Edema

12.6.4. Others (Retinal Vein Occlusion, etc.)

12.7. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

12.8. Europe Retinal Disorder Treatment Market Forecast, by Therapeutic Class

12.8.1. Anti-VEGF Agents

12.8.2. Others (Anti-inflammatory Drugs, etc.)

12.9. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

12.10. Europe Retinal Disorder Treatment Market Forecast, by Dosage Form

12.10.1. Gels

12.10.2. Eye Solutions

12.10.3. Capsules & Tablets

12.10.4. Eye Drops

12.10.5. Ointments

12.11. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

12.12. Europe Retinal Disorder Treatment Market Forecast, by Distribution Channel

12.12.1. Hospital Pharmacies

12.12.2. Retail Pharmacies

12.12.3. Online Sales

13. Asia Pacific Retinal Disorder Treatment Market Analysis

13.1. Key Findings

13.2. Asia Pacific Retinal Disorder Treatment Market Overview

13.3. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

13.4. Asia Pacific Retinal Disorder Treatment Market Forecast, by Country/Sub-region

13.4.1. Japan

13.4.2. China

13.4.3. India

13.4.4. Australia & New Zealand

13.4.5. Rest of Asia Pacific

13.5. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

13.6. Asia Pacific Retinal Disorder Treatment Market Forecast, by Disease Indication

13.6.1. Macular Degeneration

13.6.1.1. Dry Macular Degeneration

13.6.1.2. Wet Macular Degeneration

13.6.2. Diabetic Retinopathy

13.6.3. Diabetic Macular Edema

13.6.4. Others (Retinal Vein Occlusion, etc.)

13.7. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

13.8. Asia Pacific Retinal Disorder Treatment Market Forecast, by Therapeutic Class

13.8.1. Anti-VEGF Agents

13.8.2. Others (Anti-inflammatory Drugs, etc.)

13.9. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

13.10. Asia Pacific Retinal Disorder Treatment Market Forecast, by Dosage Form

13.10.1. Gels

13.10.2. Eye Solutions

13.10.3. Capsules & Tablets

13.10.4. Eye Drops

13.10.5. Ointments

13.11. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

13.12. Asia Pacific Retinal Disorder Treatment Market Forecast, by Distribution Channel

13.12.1. Hospital Pharmacies

13.12.2. Retail Pharmacies

13.12.3. Online Sales

14. Latin America Retinal Disorder Treatment Market Analysis

14.1. Key Findings

14.2. Latin America Retinal Disorder Treatment Market Overview

14.3. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

14.4. Latin America Retinal Disorder Treatment Market Forecast, by Country/Sub-region

14.4.1. Brazil

14.4.2. Mexico

14.4.3. Rest of Latin America

14.5. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

14.6. Latin America Retinal Disorder Treatment Market Forecast, by Disease Indication

14.6.1. Macular Degeneration

14.6.1.1. Dry Macular Degeneration

14.6.1.2. Wet Macular Degeneration

14.6.2. Diabetic Retinopathy

14.6.3. Diabetic Macular Edema

14.6.4. Others (Retinal Vein Occlusion, etc.)

14.7. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

14.8. Latin America Retinal Disorder Treatment Market Forecast, by Therapeutic Class

14.8.1. Anti-VEGF Agents

14.8.2. Others (Anti-inflammatory Drugs, etc.)

14.9. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

14.10. Latin America Retinal Disorder Treatment Market Forecast, by Dosage Form

14.10.1. Gels

14.10.2. Eye Solutions

14.10.3. Capsules & Tablets

14.10.4. Eye Drops

14.10.5. Ointments

14.11. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

14.12. Latin America Retinal Disorder Treatment Market Forecast, by Distribution Channel

14.12.1. Hospital Pharmacies

14.12.2. Retail Pharmacies

14.12.3. Online Sales

15. Middle East & Africa Retinal Disorder Treatment Market Analysis

15.1. Key Findings

15.2. Middle East & Africa Retinal Disorder Treatment Market Overview

15.3. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

15.4. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Country/Sub-region

15.4.1. GCC Countries

15.4.2. South Africa

15.4.3. Rest of Middle East & Africa

15.5. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

15.6. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Disease Indication

15.6.1. Macular Degeneration

15.6.1.1. Dry Macular Degeneration

15.6.1.2. Wet Macular Degeneration

15.6.2. Diabetic Retinopathy

15.6.3. Diabetic Macular Edema

15.6.4. Others (Retinal Vein Occlusion, etc.)

15.7. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

15.8. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Therapeutic Class

15.8.1. Anti-VEGF Agents

15.8.2. Others (Anti-inflammatory Drugs, etc.)

15.9. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

15.10. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Dosage Form

15.10.1. Gels

15.10.2. Eye Solutions

15.10.3. Capsules & Tablets

15.10.4. Eye Drops

15.10.5. Ointments

15.11. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

15.12. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Distribution Channel

15.12.1. Hospital Pharmacies

15.12.2. Retail Pharmacies

15.12.3. Online Sales

16. Competition Analysis

16.1. Global Retinal Disorder Treatment Market Share Analysis, by Company

16.2. Competition Matrix

16.3. Company Profile

16.3.1. Santen Pharmaceutical Co., Ltd.

16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.1.2. Financial Overview

16.3.1.3. Product Portfolio

16.3.1.4. SWOT Analysis

16.3.1.5. Strategic Overview

16.3.2. Regeneron Pharmaceuticals, Inc.

16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.2.2. Financial Overview

16.3.2.3. Product Portfolio

16.3.2.4. SWOT Analysis

16.3.2.5. Strategic Overview

16.3.3. F. Hoffmann-La Roche Ltd.

16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.3.2. Financial Overview

16.3.3.3. Product Portfolio

16.3.3.4. SWOT Analysis

16.3.3.5. Strategic Overview

16.3.4. Pfizer, Inc.

16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.4.2. Financial Overview

16.3.4.3. Product Portfolio

16.3.4.4. SWOT Analysis

16.3.4.5. Strategic Overview

16.3.5. Allergan plc

16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.5.2. Financial Overview

16.3.5.3. Product Portfolio

16.3.5.4. SWOT Analysis

16.3.5.5. Strategic Overview

16.3.6. Shire (Takeda Pharmaceutical Company Limited)

16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.6.2. Financial Overview

16.3.6.3. Product Portfolio

16.3.6.4. SWOT Analysis

16.3.6.5. Strategic Overview

16.3.7. Bayer AG

16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.7.2. Financial Overview

16.3.7.3. Product Portfolio

16.3.7.4. SWOT Analysis

16.3.7.5. Strategic Overview

16.3.8. Graybug Vision, Inc.

16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.8.2. Financial Overview

16.3.8.3. Product Portfolio

16.3.8.4. SWOT Analysis

16.3.8.5. Strategic Overview

16.3.9. Novartis AG

16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.9.2. Financial Overview

16.3.9.3. Product Portfolio

16.3.9.4. SWOT Analysis

16.3.9.5. Strategic Overview

16.3.10. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.)

16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.10.2. Financial Overview

16.3.10.3. Product Portfolio

16.3.10.4. SWOT Analysis

16.3.10.5. Strategic Overview

List of Tables

Table 01: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 02: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 03: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 04: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 08: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 09: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 10: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 11: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 12: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 14: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 15: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 16: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 17: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 18: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 20: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 21: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 22: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 23: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 25: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 26: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 27: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 28: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 29: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 30: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 31: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 32: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 33: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 34: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 35: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027